Phase 1/2 RCT in 194 adults with recent S. aureus skin/soft tissue infection: adjuvanted 5-antigen vaccine vs placebo was acceptably safe (primary outcome) but showed no efficacy against recurrence at 12 months (secondary; VE −38.1%); stopped for futility at interim analysis.
RCTn = 194
Athan et al. Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted Staphylococcus aureus Vaccine in Adults With Recent Skin and Soft Tissue Infections: An Observer-Blind, Randomized, Placebo-Controlled, Multinational Phase 1/2 Trial